- Home
- MRM vs IMRN Comparison
MRM vs IMRN Comparison
Compare MRM & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- IMRN
- Stock Information
- Founded
- MRM 2000
- IMRN 1994
- Country
- MRM Japan
- IMRN Australia
- Employees
- MRM N/A
- IMRN N/A
- Industry
- MRM Other Consumer Services
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- MRM Consumer Discretionary
- IMRN Health Care
- Exchange
- MRM Nasdaq
- IMRN Nasdaq
- Market Cap
- MRM 15.8M
- IMRN 14.4M
- IPO Year
- MRM 2020
- IMRN N/A
- Fundamental
- Price
- MRM $1.99
- IMRN $1.62
- Analyst Decision
- MRM
- IMRN
- Analyst Count
- MRM 0
- IMRN 0
- Target Price
- MRM N/A
- IMRN N/A
- AVG Volume (30 Days)
- MRM 377.0K
- IMRN 388.3K
- Earning Date
- MRM 05-22-2026
- IMRN 08-29-2025
- Dividend Yield
- MRM N/A
- IMRN N/A
- EPS Growth
- MRM N/A
- IMRN N/A
- EPS
- MRM 0.04
- IMRN N/A
- Revenue
- MRM $55,915,220.00
- IMRN $4,777,422.00
- Revenue This Year
- MRM N/A
- IMRN N/A
- Revenue Next Year
- MRM N/A
- IMRN N/A
- P/E Ratio
- MRM $47.31
- IMRN N/A
- Revenue Growth
- MRM 12.79
- IMRN 48.63
- 52 Week Low
- MRM $0.34
- IMRN $1.42
- 52 Week High
- MRM $4.45
- IMRN $2.48
- Technical
- Relative Strength Index (RSI)
- MRM 46.66
- IMRN 43.49
- Support Level
- MRM $1.98
- IMRN $1.47
- Resistance Level
- MRM $2.14
- IMRN $1.69
- Average True Range (ATR)
- MRM 0.09
- IMRN 0.11
- MACD
- MRM -0.01
- IMRN 0.01
- Stochastic Oscillator
- MRM 47.83
- IMRN 92.59
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.